Results 211 to 220 of about 3,328,268 (306)

Treatment of pulmonary embolism with fibrinolytic agents.

, 1967
Cliffton Ee
openalex   +1 more source

Effectiveness of atorvastatin, methylene blue, and lidocaine as chemical antiadhesion agents in preventing postoperative remote adhesions: a randomized controlled experimental study in a rat model. [PDF]

Ann Surg Treat Res
Kim YJ, Kang H, Lee OH, Lee SE, Hong SA, Suh SW, Choi YS.   +6 more
europepmc   +1 more source

Narrative review and creation of an institutional protocol for the use of fibrinolytics in parapneumonic effusion in children. [PDF]

J Pediatr (Rio J)
Frogeri FG, Fraga AMA, Marson FAL, Filho AGO, Miranda ML, Bustorff-Silva JM.   +5 more
europepmc   +1 more source

Treatment outcomes in pediatric empyema: a retrospective observational study from a tertiary center in Dubai, United Arab Emirates. [PDF]

Pediatr Surg Int
Al Blooshi M, Ahmad M, Al Shamali F, Uddin W, Jaber G, Al Marzouqi M, Hiremath A, Kader MA, Gupta V.   +8 more
europepmc   +1 more source

[Fibrinolytic agents in peripheral vascular diseases].

Angiologia, 1998
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Development of New Fibrinolytic Agents

Current Pharmaceutical Design, 2006
Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic, which removes the thrombus from the circulation.
Shigeru, Ueshima, Osamu, Matsuo
openaire   +3 more sources

Fibrinolytic Agents: Mechanisms of Activity and Pharmacology

Thrombosis and Haemostasis, 1995
Fibrinolytic (thrombolytic) agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin. Agents available for clinical use are: the physiologic tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA)--either in a single chain (scu-PA ...
H R, Lijnen, D, Collen
openaire   +3 more sources

Synthetic fibrinolytic agents

Progress in Cardiovascular Diseases, 1979
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J F, Davidson, I D, Walker
openaire   +2 more sources

[Enzymatic fibrinolytic agents].

Annales de l'anesthesiologie francaise, 1979
Urokinase (UK) and streptokinase (SK) transform plasminogen into plasmin by rupture of a ARG-VAL bond and the liberation of a peptide with a molecular weight of 6000 to 8000. Urokinase is a physiological activator with a direct action. By contrast, streptokinase is an enzyme of bacterial origin and two hypotheses may be advanced to explain its ...
M, Jamet, C, Granthil, G, Levy
openaire   +2 more sources